FOUNDING COHORT · MEMBER #024 · SOVEREIGN-GRADE NETWORK · CHARTER SEAT
SYS · FHIN-FND · v2.4.1
CLIENT Trial Signal Shield Command Growth Enterprise FHIN Observer Contributor Researcher Institutional Founding Community →
Demo Environment · All signals, scores, and member identifiers are illustrative. No live API connections in this view.
SYS · FHIN-FND-DEMO · v2.4.1

Founding Cohort Workspace

You helped shape this network. Your charter privileges, your signals, your fellow founders. CHARTER SEAT · SOURCE-TRACED

#024 CHARTER
FHIN · FOUNDING COHORT

Charter Member · Seat #024

Joined · 14 Jan 2026 Cohort cap · 100 seats Status · Active · verified

"What changes when you're inside the cohort that shaped this network?"

PRIVILEGE · 01
All-Tier Network Access

Read across every FHIN tier — Observer, Contributor, Researcher, Institutional — without gating. Every confidence-scored signal, every adversarial validation thread, visible to you.

Full network read
PRIVILEGE · 02
Early Feature Window

A 90-day preview window on every new capability before general release. You shape the network's decision integrity layer in the room where it's being built — not after.

90-day preview
PRIVILEGE · 03
Annual Symposium Invite

September 2026 · charter-only gathering. Working sessions on signal methodology, cross-cohort introductions, and the year-ahead roadmap. One seat per founder.

Sept 2026 · reserved
MO
✓

Dr. Maya Okonkwo, MD, MPH

Associate Professor · Stanford Medicine · FHIN Verified Contributor

Translational immuno-oncology, with focus on adversarial-validation methodology for surrogate-endpoint trials. Charter contributor to the FHIN signal network — every submission source-traced, confidence-scored, and adjudicated by the swarm before it enters the decision integrity layer.

Affiliation · Stanford Medicine / Stanford Cancer Institute
Focus · IO surrogate endpoints · ccRCC · NSCLC
Verified · credential-reviewed · charter cohort
Publications
31
4 under peer review · 2 charter-cited
Signals Contributed
62
+9 this quarter · confidence-scored
Network Connections
184
Verified peers across 22 institutions
My Signals · Charter-Contributed Intelligence
View full feed →
PROCEED · 0.89 FOUND-SIG-2026-0524-001·Oncology · NSCLC·4h ago
Adversarial validation upholds KRAS-G12C / SHP2 combo signal across 3 swarm cohorts
Charter cohort cross-read produced PROCEED at 0.89 confidence after 14 source-traces. Adversarial agents converged on durable-response mechanism within 6 cycles.
DELAY · 0.58 FOUND-SIG-2026-0522-007·Surrogate endpoints·2d ago
PFS-as-surrogate signal in IO-naïve NSCLC — adversarial agents flag confounded readout
DELAY pending crossover-adjusted reanalysis. Swarm disagreement at 0.58 — three agents called confound, two called clean signal. Charter cohort under deliberation.
PROCEED · 0.92 FOUND-SIG-2026-0519-012·Regulatory · EMA·5d ago
EMA CHMP draft opinion signals tumor-agnostic acceptance for HIF-2α class
Four sovereign-grade source-traces confirm CHMP rapporteur language. Verified intelligence, not interpretation — adversarial validation cleared at 0.92.
KILL · 0.94 FOUND-SIG-2026-0515-019·Trial design·9d ago
Phase 2 expansion cohort design fails decision-integrity audit — null endpoint inevitable
Charter audit killed the design hypothesis at 0.94. Adversarial validation surfaced power calculation error pre-enrollment. Decision integrity preserved before patient harm.
PROCEED · 0.81 FOUND-SIG-2026-0510-024·Mechanism · TIM-3·14d ago
TIM-3 + LAG-3 combinatorial blockade restores T-cell exhaustion reversal in IO-experienced cohort
Source-traced through 5 institutional contributors. Confidence reflects swarm agreement across charter-cohort cross-read, not single-source assertion.
PROCEED · 0.86 FOUND-SIG-2026-0504-031·Market · Merck pipeline·20d ago
Merck Q1 R&D-day language signals quiet pivot away from binary IO-combo bets
Source-traced through earnings transcript + investor-day Q&A. Confidence-scored against 7 internal pipeline reads from charter cohort.
DELAY · 0.64 FOUND-SIG-2026-0428-044·Resistance · ccRCC·26d ago
PBRM1-mutant ccRCC IO-resistance hypothesis splits charter cohort — DELAY for replication
Swarm disagreement at 0.64. Charter cohort requested replication cohort before lifting DELAY. Decision integrity over publication speed.
My Publications · Peer-Reviewed Record
View all 31 →
Charter Methodology: Adversarial Validation as a Standard for AI-Generated Biopharma Evidence
NEJM · 2026 · senior author · FHIN charter paper
218 cites
Published
Confidence-scored decision integrity: a network-mediated alternative to binary trial reads
Nature Medicine · 2026 · co-first
163 cites
Published
Source-traced intelligence reduces false-confidence bias in immuno-oncology surrogate endpoints
JCO · 2025 · senior author
241 cites
Published
PROCEED / DELAY / KILL: a verdict framework for AI-mediated clinical signal interpretation
JAMA Oncology · 2026 · under review
— pending
Under review
Charter-cohort cross-read methodology for decision-integrity preservation in expansion trials
Lancet Oncology · 2026 · draft circulated
— pending
Under review
Founding Cohort · Fellow Charter Members
Browse cohort directory →
#001
DC
Dr. D. Chen
Dana-Farber
#004
EV
Dr. E. Vance
MSK
#007
PR
Dr. P. Ramirez
MD Anderson
#009
KS
Dr. K. Sato
NCC Tokyo
#012
JM
Dr. J. Müller
Charité
#015
AO
Dr. A. Olusegun
Yale
#017
LB
Dr. L. Brennan
UCSF
#020
SH
Dr. S. Hayes
Hopkins
#023
RN
Dr. R. Nguyen
Mayo Clinic
#027
FP
Dr. F. Petrov
Karolinska
#031
TJ
Dr. T. Jang
Samsung Med
#035
CH
Dr. C. Hoffman
Fred Hutch
4 / 10
Invites used
CHARTER INVITE PRIVILEGE · 2026

You've invited 4 of 10 colleagues this year

Charter members hold a finite number of verified-intake invitations per calendar year. Who would you stake your decision integrity on? Each invitation enters the source-traced verification queue — confidence-scored before any seat is offered.

Send a verified invitation →
CHARTER PRIVILEGE · ANNUAL CONVENING

Annual Symposium · September 2026

One seat per founder · charter cohort only. Working sessions on signal methodology, cross-cohort introductions, and the year-ahead roadmap for the network you helped build. Sovereign-grade conversations, off the record, source-traced afterward.

Reserve your seat → 17–19 SEP 2026 · MENLO PARK · 100 SEATS · INVITATION VERIFIED
Submit a Signal · Charter Contribution
FOUNDING PRIVILEGE · OPEN QUEUE

Submitted signals enter the FHIN validation queue. Charter submissions are source-traced and confidence-scored before entering the decision intelligence layer. Full submission form available in the member portal.

My Contribution Score
Score active — member view only
Your contribution score reflects signal submission volume, validation participation rate, and source-trace quality across the FHIN network. Founding cohort scores carry a permanent charter weight multiplier. Full score breakdown visible to FHIN members and your institutional account.
Signals submittedMembers only
Validation rateMembers only
Source-trace qualityMembers only
Charter multiplierActive ✓
Upgrade Path · FHIN Network

Advance from Founding Contributor to Researcher

Founding cohort members are eligible for an expedited pathway to Researcher tier. Researcher status unlocks primary evidence production, dossier co-authorship, and direct adversarial validation access — the evidence layer above the credibility layer you currently hold.

Observer Visibility
→
Founding Credibility ✓
→
→
Institutional Governance
→
Enterprise Deployment

What Researcher tier unlocks

Primary Evidence Production
Submit primary research signals with full source-trace attribution. Your work enters the confidence-scoring layer as a primary source — not just validation input.
Dossier Co-Authorship
Co-author live intelligence dossiers with other credentialed researchers. Your contributions are attributed, versioned, and visible to enterprise accounts.
Adversarial Validation Access
Participate directly in the swarm validation layer — challenge signals, co-sign verdicts, and contribute to the PROCEED / DELAY / KILL confidence scores.
Apply for Researcher upgrade → Founding expedited review · 3–5 business days